Seroprevalence of hepatitis B virus surface antigens and antibodies among healthcare workers in selected hospitals in Rivers State, Nigeria
Main Article Content
Abstract
Background: Hepatitis B virus (HBV) infection is a major cause of liver-associated death and disability affecting over 350 million people globally. Individuals with chronic hepatitis B may progress to a more severe and deadly form of disease, mainly cirrhosis, end-stage liver disease and hepatocellular carcinoma (HCC). Healthcare workers (HCWs) are at a high risk of occupational exposure to HBV infection.
Objectives: The objectives of the study were to determine the risk factors and seroprevalence of HBV infection and protective antibodies in HCWs at selected hospitals in Port Harcourt.
Methods: Socio-demographic data and venous blood specimens were collected from consenting HCWs in the selected hospitals and tested for the presence of HBV immunological markers using immuno-chromogenic and enzyme-linked immunosorbent assay methods. Data generated was analyzed using descriptive statistics and chi square.
Results: This study revealed low levels of HBV infection (2%), high HB vaccination coverage (98%) and HBsAg - anti-HBs double seropositivity in chronic carriers that increases the risk of HCC and liver failure. Having a family member with liver disease, history of blood transfusion, blood donation and needle stick injury were significant risk factors (p< 0.05) for HBV infection. However, a history of blood splash was the only significant risk factor for anti-HBs seronegative HCWs.
Conclusion: HBV infection is present among HCW in Rivers state. From the findings, the infection and its attendant protective antibodies could be attributed to some invasive risk factors. Following from these, there is an important need for more awareness and public health education on prevention of HBV infection in order to achieve WHO Global health Sector Strategic plan by year 2030.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Hyams KC. (1995). Risks of chronicity following acute hepatitis B virus infection: A review. Clinical Infectious Diseases. 20(4):992-1000.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. (2018). Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer Journal for Clinicians. 68(6):394-424.
Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. (2016). Global burden of cancers attributable to infections in 2012: A synthetic analysis. Lancet Global Health. 4(9):e609-616.
Beasley RP. (1988). Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 61(10):1942-1956.
Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ, Taiwan Community-Based Cancer Screening Project Group. (2002). Hepatitis B e antigen and the risk of hepatocellular carcinoma. New England Journal of Medicine. 347(3):168-174.
Zampino R, Pisaturo MA, Cirillo G, Marrone A, Macera M, Rinaldi L, Stanzione M, Durante-Mangoni E, Gentile I, Sagnelli E, Signoriello G, Del Giudice EM, Adinolfi LE, Coppola N. (2015). Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. Annals of Hepatology. 14(1):75-82.
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. (2019). A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nature Reviews Gastroenterology Hepatology. 16(10):589-604.
Alese OO, Alese MO, Ohunakin A, Oluyide PO. (2016). Seroprevalence of hepatitis B surface antigen and occupational risk factors among health care workers in Ekiti State, Nigeria. Journal of Clinical Diagnostic Research. 10(2):LC16-18.
Ijoma UN, Meka IA, Omotowo B, Nwagha TU, Obienu O, Onodugo OD, Onyekonwu CL, Okoli EV, Ndu AC, Ugwu EO. (2021). Sero-prevalence of hepatitis B virus infection: A cross-sectional study of a large population of health care workers in Nigeria. Nigerian Journal of Clinical Practice. 24(1):38-44.
Fadil RA, Abdelmutalab NA, Abdelhafeez SA, Mazi W, Algamdi S, Shelwy MM, Bouafia N, Alzahrani SE. (2021). Pattern and risk factors of sharp object injuries among health care workers in two tertiary hospitals, Al Taif-Kingdom of Saudi Arabia 2016- 2018. Saudi Journal of Biological Sciences. 28(11):6582-6585.
Mmbaga EJ, Moen K, Leyna GH, Mpembeni R, Leshabari MT. (2018). HIV prevalence and associated risk factors among men who have sex with men in Dar es Salaam, Tanzania. Journal of Acquired Immune Deficiency Syndrome. 77(3):243-249.
Jary A, Dienta S, Leducq V, Le Hingrat Q, Cisse M, Diarra AB, Fofana DB, Ba A, Baby M, Achenbach CJ, Murphy R, Calvez V, Marcelin AG, Maiga AI. (2019). Seroprevalence and risk factors for HIV, HCV, HBV and syphilis among blood donors in Mali. BMC Infectious Diseases. 19(1):1064.
Otegbayo JA, Fasola FA, Abja A. (2003). Prevalence of hepatitis B surface and E antigens, risk factors for viral acquisition and serum transaminase among blood donors in Ibadan, Nigeria. Tropical Gastroenterology. 24(4):196-197.
Moradi G, Mohamadi P, Zareie B, Rasouli MA, Gouya MM, Jafari S. (2020). Prevalence of and risk factors for HBV and HCV among incarcerated people who inject drugs in Iran: A cross sectional study. BMC Infectious Diseases. 20(1):806. 148 West African Journal of Pharmacy (2023) 34 (2)
Mhalla S, Hammoud R, Frih A, Kadri Y, El Argoubi A, Elmay M, Mastouri M. (2018). Prevalence and risk factors of hepatitis B and C among hemodialysis patients in Tunisia. Medical Malpractice and Infection. 48(3):175-179.
Guo Z, Shi XH, Feng YL, Wang B, Feng LP, Wang SP, Zhang YW. (2013). Risk factors of HBV intrauterine transmission among HBsAg-positive pregnant women. Journal of Viral Hepatitis. 20(5):317-321.
Lyu X, Liu K, Chen Y, Wang Z, Yao J, Cai G, Jiang Z, Jiang J, Gu H. (2016). Analysis of risk factors associated with the development of hepatocellular carcinoma in chronic HBV-infected Chinese: A meta-analysis. International Journal of Environmental Research and Public Health. 13(6):604.
Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, American Association for the Study of Liver Diseases. (2016). AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 63(1):261-283.
LeFevre ML, Force USPST. (2014). Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive services task force recommendation statement. Annals of Internal Medicine. 161(1):58-66.
Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, Rodewald LE, Douglas JM, Janssen RS, Ward JW, Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). (2006). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of adults. Mortality and Morbidity Weekly Report: Recommendation Reports. 55(RR-16):1-33; quiz CE1-4.
Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, Neitzel SM, Ward JW, Centers for Disease Control and Prevention (CDC). (2008). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Mortality and Morbidity Weekly Report: Recommendation Reports. 57(RR- 8):1-20.
Abara WE, Qaseem A, Schillie S, McMahon BJ, Harris AM, Abraham GM, Centor R, DeLong DM, Gantzer HE, Horwitch CA, Humphrey LL, Jokela JA, Li JMW, Lohr LH, Lopez AM, McLean RM (2017). Hepatitis B vaccination, screening, and linkage to care: Best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention. Annal of Internal Medicine. 167(11):794-804.
Lok AS, Zoulim F, Dusheiko G, Ghany MG. (2017). Hepatitis B cure: From discovery to regulatory approval. Hepatology. 66(4):1296-1313.
Whitley E, Ball J. (2002). Statistics review 4: Sample size calculations. Critical Care. 6(4):335-341.
Ogundele OA, Olorunsola A, Bakare B, Adegoke IA, Ogundele T, Fehintola FO, Okotie S. (2021). Seroprevalence and knowledge of hepatitis B and C among health care workers in a specialist hospital in Nigeria. European Journal of Preventive Medicine. 5(1):7-12.
Ejele OA, Ojule AC. (2003). Hepatitis B antigenemia (HBsAg): Risk of occupational exposure in a chemical pathology laboratory in Nigeria. Nigeria Journal of Clinical Practice. 6(2):99-101.
Ola SO, Odaibo GN, Olaleye OD, Ayoola EA. (2012). Hepatitis B and E viral infections among Nigerian healthcare workers. African Journal of Medicine and Medical Sciences. 41(4):387-391.
Musa BM, Bussell S, Borodo MM, Samaila AA, Femi OL. (2015). Prevalence of hepatitis B virus infection in Nigeria, 2000-2013: A systematic review and meta-analysis. Nigeria Journal of Clinical Practice. 18(2):163-172.
Pondé RA. (2013). Atypical serological profiles in hepatitis B virus infection. European Journal of Clinical Microbiology and Infectious Diseases. 32(4):461-476. 149 West African Journal of Pharmacy (2023) 34 (2)
Ikobah J, Okpara H, Elemi I, Ogarepe Y, Udoh E, Ekanem E. (2016). The prevalence of hepatitis B virus infection in Nigerian children prior to vaccine introduction into the national programme on immunization schedule. Pan African Medical Journal. 23:128.
Simidele OM, Oladimeji A, Joseph AA, Aduayi V, Samuel NI. (2018). Burden of hepatitis B viral infection among workers in a tertiary health
institution in southwestern Nigeria. Open Journal of Medical Microbiology. 8:85-97.
Krajden M, McNabb G, Petric M. (2005). The laboratory diagnosis of hepatitis B virus. Canadian Journal of Infectious Diseases and Medical
Microbiology. 16(2):65-72.
Jiang X, Chang L, Yan Y, Wang L. (2021). Paradoxical HBsAg and anti-HBs coexistence among chronic HBV infections: Causes and consequences. International Journal of Biological Sciences. 17(4):1125-1137.
Jin ZZ, Jin FF, Liu X, Liu N, Wen F, Lou JL. (2019). Coexistence of low levels of HBsAg and high levels of anti-HBs may increase risk of hepatocellular carcinoma in chronic hepatitis B patients with high HBV load. Brazilian Journal of Infectious Diseases. 23(5):343-351.
Kwak MS, Chung GE, Yang JI, Yim JY. (2019). Long- term outcomes of HBsAg/anti-HBs double-positive versus HBsAg single-positive patients with chronic hepatitis B. Scientific Reports. 9(1):19417.